The politics of drug reimbursement in England, France and Germany
نویسندگان
چکیده
General information and drug reimbursement in the study countries, 2003 This study forms part of the IRDES programme of research on pharmaceutical policy, and compares the regulatory framework and contents of baskets of reimbursed drugs in three European countries: France, Germany and England. It is a contribution to the current debate on reimbursement of drugs of insufficient therapeutic value, which the High Authority on Health has recently proposed will no longer be reimbursed.
منابع مشابه
Cholecystectomy and Diagnosis-Related Groups (DRGs): Patient Classification and Hospital Reimbursement in 11 European Countries
Background As part of the EuroDRG project, researchers from eleven countries (i.e. Austria, England, Estonia, Finland, France, Germany, Ireland, Netherlands, Poland, Sweden, and Spain) compared how their Diagnosis-Related Groups (DRG) systems deal with cholecystectomy patients. The study aims to assist surgeons and national authorities to optimize their DRG systems. Methods National or region...
متن کاملمطالعه تطبیقی نظام های پرداخت بهای خدمات بیمارستانی توسط سازمانهای بیمه گر در چندکشور منتخب و ارائه الگوی مناسب برای ایران
Regarding an increase in the number of insured people and costs of treatment services, insurance organizations encounter problems in paying claims of their contractees. So that a delay in the payment of contractee hospital costs has made them reluctant in accepting and visiting the insured people. In order to compensate their fiscal deficit and prevent its increase, insurance organizations in I...
متن کاملHeterogeneity of European DRG Systems and Potentials for a Common Eurodrg System; Comment on “Cholecystectomy and Diagnosis-Related Groups (DRGs): Patient Classification and Hospital Reimbursement in 11 European Countries”
Diagnosis-Related Group (DRG) systems across Europe are very heterogeneous, in particular because of different classification variables and algorithms as well as costing methodologies. But, given the challenge of increasing patient mobility within Europe, health systems are forced to incorporate a common patient classification language in order to compare and identify similar patients e.g. for ...
متن کاملOrphan Drugs Assessment in Germany: A Comparison with Other International HTA Agencies.
• Germany did not issue any negative recommendations for any of the 20 Orphan Drug assessments – However, 7 assessments (35%) where the additional benefit was not quantifiable would have been negative if the products did not have an EMA Orphan Drug designation and a legislated «implicit additional clinical benefit» – Potential changes to the German drug assessment mechanism could impact this on...
متن کاملClinical Indications, Utilization, and Funding of Bariatric Surgery in Europe
PURPOSE The objective of this study was to evaluate the current utilization, the level of endorsement by professional societies, and health technology assessment bodies, as well as the reimbursement levels for bariatric surgery in European countries. MATERIALS AND METHODS We performed an analysis of the indications for bariatric surgery based on national clinical and commissioning guidelines,...
متن کامل